These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 35978267)

  • 1. The NLRP3 inflammasome contributes to inflammation-induced morphological and metabolic alterations in skeletal muscle.
    Eggelbusch M; Shi A; Broeksma BC; Vázquez-Cruz M; Soares MN; de Wit GMJ; Everts B; Jaspers RT; Wüst RCI
    J Cachexia Sarcopenia Muscle; 2022 Dec; 13(6):3048-3061. PubMed ID: 35978267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The NLRP3 inflammasome modulates glycolysis by increasing PFKFB3 in an IL-1β-dependent manner in macrophages.
    Finucane OM; Sugrue J; Rubio-Araiz A; Guillot-Sestier MV; Lynch MA
    Sci Rep; 2019 Mar; 9(1):4034. PubMed ID: 30858427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of NLRP3 inflammasome inhibition by MCC950 on LPS-induced pancreatic adenocarcinoma inflammation.
    Yaw ACK; Chan EWL; Yap JKY; Mai CW
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2219-2229. PubMed ID: 32507974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of the NLRP3 Inflammasome Increases the IL-1β Level and Decreases GLUT4 Translocation in Skeletal Muscle during Insulin Resistance.
    Américo-Da-Silva L; Aguilera J; Quinteros-Waltemath O; Sánchez-Aguilera P; Russell J; Cadagan C; Meneses-Valdés R; Sánchez G; Estrada M; Jorquera G; Barrientos G; Llanos P
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MCC950 blocks enhanced interleukin-1β production in patients with NLRP3 low penetrance variants.
    Schuh E; Groß CJ; Wagner D; Schlüter M; Groß O; Kümpfel T
    Clin Immunol; 2019 Jun; 203():45-52. PubMed ID: 30974290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition.
    Vande Walle L; Stowe IB; Šácha P; Lee BL; Demon D; Fossoul A; Van Hauwermeiren F; Saavedra PHV; Šimon P; Šubrt V; Kostka L; Stivala CE; Pham VC; Staben ST; Yamazoe S; Konvalinka J; Kayagaki N; Lamkanfi M
    PLoS Biol; 2019 Sep; 17(9):e3000354. PubMed ID: 31525186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of NLRP3 inflammasome by MCC950 improves the metabolic outcome of islet transplantation by suppressing IL-1β and islet cellular death.
    Matsuoka T; Yoshimatsu G; Sakata N; Kawakami R; Tanaka T; Yamada T; Yoshida Y; Hasegawa S; Kodama S
    Sci Rep; 2020 Oct; 10(1):17920. PubMed ID: 33087823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of the ROS/TXNIP/NLRP3 pathway disrupts insulin-dependent glucose uptake in skeletal muscle of insulin-resistant obese mice.
    Russell-Guzmán J; Américo-Da Silva L; Cadagan C; Maturana M; Palomero J; Estrada M; Barrientos G; Buvinic S; Hidalgo C; Llanos P
    Free Radic Biol Med; 2024 Sep; 222():187-198. PubMed ID: 38897422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of the NLRP3 Inflammasome Is Associated with Valosin-Containing Protein Myopathy.
    Nalbandian A; Khan AA; Srivastava R; Llewellyn KJ; Tan B; Shukr N; Fazli Y; Kimonis VE; BenMohamed L
    Inflammation; 2017 Feb; 40(1):21-41. PubMed ID: 27730320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.
    Mridha AR; Wree A; Robertson AAB; Yeh MM; Johnson CD; Van Rooyen DM; Haczeyni F; Teoh NC; Savard C; Ioannou GN; Masters SL; Schroder K; Cooper MA; Feldstein AE; Farrell GC
    J Hepatol; 2017 May; 66(5):1037-1046. PubMed ID: 28167322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of NLRP3 Inflammasome Prevents LPS-Induced Inflammatory Hyperalgesia in Mice: Contribution of NF-κB, Caspase-1/11, ASC, NOX, and NOS Isoforms.
    Dolunay A; Senol SP; Temiz-Resitoglu M; Guden DS; Sari AN; Sahan-Firat S; Tunctan B
    Inflammation; 2017 Apr; 40(2):366-386. PubMed ID: 27924425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of NLRP3 inflammasome ameliorates podocyte damage by suppressing lipid accumulation in diabetic nephropathy.
    Wu M; Yang Z; Zhang C; Shi Y; Han W; Song S; Mu L; Du C; Shi Y
    Metabolism; 2021 May; 118():154748. PubMed ID: 33675822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MCC950, a NLRP3 inhibitor, ameliorates lipopolysaccharide-induced lung inflammation in mice.
    Wang L; Lei W; Zhang S; Yao L
    Bioorg Med Chem; 2021 Jan; 30():115954. PubMed ID: 33360197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MCC950, a selective NLPR3 inflammasome inhibitor, improves neurologic function and survival after cardiac arrest and resuscitation.
    Jiang M; Li R; Lyu J; Li X; Wang W; Wang Z; Sheng H; Zhang W; Karhausen J; Yang W
    J Neuroinflammation; 2020 Aug; 17(1):256. PubMed ID: 32867797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MCC950 attenuated early brain injury by suppressing NLRP3 inflammasome after experimental SAH in rats.
    Luo Y; Lu J; Ruan W; Guo X; Chen S
    Brain Res Bull; 2019 Mar; 146():320-326. PubMed ID: 30716395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipopolysaccharide (LPS) stimulation of Pancreatic Ductal Adenocarcinoma (PDAC) and macrophages activates the NLRP3 inflammasome that influences the levels of pro-inflammatory cytokines in a co-culture model.
    Sivam HGP; Chin BY; Gan SY; Ng JH; Gwenhure A; Chan EWL
    Cancer Biol Ther; 2023 Dec; 24(1):2284857. PubMed ID: 38018872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of NLRP3 Inhibitor as a Non-Hormonal Treatment for ovarian endometriosis.
    Murakami M; Osuka S; Muraoka A; Hayashi S; Bayasula ; Kasahara Y; Sonehara R; Hariyama Y; Shinjo K; Tanaka H; Miyake N; Yoshita S; Nakanishi N; Nakamura T; Goto M; Kajiyama H
    Reprod Biol Endocrinol; 2022 Mar; 20(1):58. PubMed ID: 35351143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension.
    Krishnan SM; Ling YH; Huuskes BM; Ferens DM; Saini N; Chan CT; Diep H; Kett MM; Samuel CS; Kemp-Harper BK; Robertson AAB; Cooper MA; Peter K; Latz E; Mansell AS; Sobey CG; Drummond GR; Vinh A
    Cardiovasc Res; 2019 Mar; 115(4):776-787. PubMed ID: 30357309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of NLRP3 inflammasome up-regulates TREM-1 expression in murine macrophages via HMGB1 and IL-18.
    Zhong WJ; Duan JX; Liu T; Yang HH; Guan XX; Zhang CY; Yang JT; Xiong JB; Zhou Y; Guan CX; Li Q
    Int Immunopharmacol; 2020 Dec; 89(Pt A):107045. PubMed ID: 33045564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NLRP3 inflammasome up-regulates major histocompatibility complex class I expression and promotes inflammatory infiltration in polymyositis.
    Xia P; Shao YQ; Yu CC; Xie Y; Zhou ZJ
    BMC Immunol; 2022 Aug; 23(1):39. PubMed ID: 35965334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.